Trial · NCT00535405
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 | Atorvastatin 10 mg | -39.5 | 95% Confidence Interval -41.4 to -37.5 | Percent change in LDL-C | |
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 | Ezetimibe 10 mg/Simvastatin 20 mg | -54.2 | 95% Confidence Interval -56.1 to -52.2 | Percent change in LDL-C | |
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 | Atorvastatin 20 mg | -46.6 | 95% Confidence Interval -48.6 to -44.7 | Percent change in LDL-C | |
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 | Ezetimibe 10 mg/Simvastatin 40 mg | -59.1 | 95% Confidence Interval -61.0 to -57.1 | Percent change in LDL-C | |
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 | Atorva 40 mg | -50.8 | 95% Confidence Interval -52.8 to -48.9 | Percent change in LDL-C | |
| Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12 | Atorvastatin 10 mg | 9.9 | Standard Error 1.92 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12 | Ezetimibe 10 mg/Simvastatin 20 mg | 51.3 | Standard Error 3.28 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12 | Atorvastatin 20 mg | 26.1 | Standard Error 2.85 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12 | Ezetimibe 10 mg/Simvastatin 40 mg | 68.2 | Standard Error 3.03 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12 | Atorva 40 mg | 38.1 | Standard Error 3.14 | Percent of Patients | |
| Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | Atorvastatin 10 mg | 45.0 | Standard Error 3.20 | Percent of Patients | |
| Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | Ezetimibe 10 mg/Simvastatin 20 mg | 69.0 | Standard Error 3.04 | Percent of Patients | |
| Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | Atorvastatin 20 mg | 61.3 | Standard Error 3.16 | Percent of Patients | |
| Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | Ezetimibe 10 mg/Simvastatin 40 mg | 82.1 | Standard Error 2.50 | Percent of Patients | |
| Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12 | Atorva 40 mg | 69.9 | Standard Error 2.97 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12 | Atorvastatin 10 mg | 58.7 | Standard Error 3.17 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12 | Ezetimibe 10 mg/Simvastatin 20 mg | 83.6 | Standard Error 2.43 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12 | Atorvastatin 20 mg | 76.9 | Standard Error 2.73 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12 | Ezetimibe 10 mg/Simvastatin 40 mg | 90.3 | Standard Error 1.93 | Percent of Patients | |
| Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12 | Atorva 40 mg | 79.5 | Standard Error 2.61 | Percent of Patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00535405/results